Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797376 | 0.91 | NPSR1 (0.31) | NPSR1MAPT | |
| SCHEMBL19797358 | 0.91 | LMNA (0.32) | LMNANPSR1GAAMAPTHTT | |
| SCHEMBL19797374 | 0.87 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL13832997 | 0.86 | NPSR1 (0.32) | NPSR1KDM4EATML3MBTL1MAPT | |
| SCHEMBL19797354 | 0.85 | LMNA (0.40) | LMNACYP1A2GAAMAPTHTT | |
| SCHEMBL23431270 | 0.85 | LMNA (0.33) | LMNAGAAMAPTHTTKMT2A | |
| SCHEMBL19797378 | 0.84 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL19797359 | 0.84 | LMNA (0.40) | LMNACYP1A2GAAMAPTHTT | |
| SCHEMBL17614686 | 0.82 | KDM4E (0.46) | NPSR1KDM4EATML3MBTL1CYP1A2 | |
| SCHEMBL13365990 | 0.81 | KDM4E (0.49) | NPSR1KDM4EATML3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10388889-B2 | Substituted phosphines as components of organic light-emitting devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CYP1B1 | LMNA 2798/4885NPSR1 4005/4885KDM4E 3119/4885 |
| US-10388889-B2 | Substituted phosphines as components of organic light-emitting devices | CRY1, CRY2, PER2 | LMNA 3701/4885NPSR1 2792/4885KDM4E 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.